Inventaire - teman dan komunitas anda adalah perpustakaan terbaik

IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.

pengarang

Ana Marquez

Francisco J. García-Hernandez

Raquel Ríos-Férnandez

Norberto Ortego-Centeno

M Francisca González-Escribano

José Luis Callejas-Rubio

Rocío González-León

José Cabeza Barrera

Enrique de Ramon Garrido Ed

diterbitkan dalam: Molecular Biology Reports

tanggal publikasi: 2013-05-05

subyek utama: Rituximab, Lupus eritematosus sistemik

Cites articles 45

Date

Judul

Pengarang

2012-02-25

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
2011-10

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation
2011-05-13

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Roland Veelken, Rebecca Fischer-Betz, Ulf Müller-Ladner, Andrea Rubbert-Roth, Bernd C Kieseier, Ulf Ziemann, Heinz Wiendl, Hans-Peter Tony, Christof Specker, Michael Sticherling, Rüdiger Eming, Michael Hertl
2011-12-21

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens
2011-08-26

An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus
2010-12-01

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Lisa G van Baarsen, Paul P Tak
2010-02-01

Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus

Juan-Manuel Anaya, Adriana Rojas-Villarraga, Güher Saruhan-Direskeneli
2010-06-16

Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance

Jade Hollis-Moffatt, Ruth Topless, Nicola Dalbeth, Andrew Harrison, Gregory T. Jones, Lisa Stamp, Tony Merriman, Peter Gow, Andre van Rij
2010-06

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment

John D Isaacs, Anne Barton, Kimme L. Hyrich, Ann W Morgan, Anthony G Wilson, Laura E Gibbons, Catherine Potter
2010-01-01

Pharmacogenetics in treatment of rheumatoid arthritis

Henk-Jan Guchelaar
2010-04-01

Rituximab: mechanism of action

George J Weiner
2010-07-01

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas

Koen van Besien
2010-07-01

Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

Manuel Ramos-casals
2010-07-01

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy

Lars Alfredsson, Jane Worthington, Anne Barton, Candace Guiducci, Annette van der Helm-van Mil, Niek de Vries, John D Isaacs, Leonid Padyukov, Lars Klareskog, Irene van der Horst-Bruinsma, Peter K. Gregersen, Paul P Tak, Tom Huizinga, Elizabeth W Karlson, Kimme L. Hyrich, Lindsey A. Criswell, Michael F Seldin, Nancy A Shadick, Michael E Weinblatt, Rene E Toes, Robert M Plenge, J Bart A Crusius, Gert Jan Wolbink, S Louis Bridges, Larry Moreland, Soumya Raychaudhuri, Cornelia F Allaart, Saedis Saevarsdottir, Johan Askling, Franak Batliwalla, Sara Wedrén, Marlena Kern, Ann W Morgan, Anthony G Wilson, Marieke Herenius
2009-01-01

Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response

Kimme L. Hyrich
2009-03-01

Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis

Rene E Toes, Carine Wouters, Eline Slagboom
2009-05-01

Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis.

Rene E Toes, Tom Huizinga, Nina A Daha, Willem Verduijn
2009-03-20

Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study

Elisabeth Petit-Teixeira, Stefano Bombardieri
2009-04-22

Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma
2008-06-01

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy

Paul Emery, Gerd-Rüdiger Burmester
2008-10-01

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.

Andy C Rawstron, Edward Marc Vital, Dennis McGonagle, Paul Emery
2008-04

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity
2008-03-28

A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci

Jane Worthington, Carol Wise, Pui-Yan Kwok, Ian Bruce, Anne M. Bowcock, Anne Barton, Wilson Liao, James G. Krueger, Shenghui Duan, Alan Menter, Cynthia A Helms, Clive R Pullinger
2008-11-01

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

Manuel Ramos-casals
2008-12-12

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

Kengo Takeuchi
2008-07-01

Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.

Keitaro Matsuo
2008-11-12

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

Dario Neri
2007-02-01

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis
2007-10-24

Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases

Alexandra Zhernakova, David A van Heel, Cisca Wijmenga, Behrooz Z. Alizadeh, Lude Franke, Barbara Franke, Marcel D. Posthumus, Bobby Koeleman, Marianna R Bevova
2007-10-25

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

Julie Roda
2007-01-01

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma
2007-05-02

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

Sigitas Verselis, Xavier Leleu, Kenneth C. Anderson

Artikel - wd:Q43693855

Selamat datang di Inventaire

perpustakaan teman-teman dan komunitas anda

pelajari lebih lanjut